These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 6247969)

  • 1. Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo.
    Field HJ; Darby G
    Antimicrob Agents Chemother; 1980 Feb; 17(2):209-16. PubMed ID: 6247969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of latent infections in mice inoculated with herpes simplex virus which is clinically resistant to acyclovir.
    Field HJ; Lay E
    Antiviral Res; 1984 Apr; 4(1-2):43-52. PubMed ID: 6331304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acyclovir, oxetanocin-G, and carbocyclic oxetanocin-G in combinations on the replications of herpes simplex virus type 1 and type 2 in Vero cells.
    Saijo M; Suzutani T; Yoshida I
    Tohoku J Exp Med; 1992 May; 167(1):57-68. PubMed ID: 1333651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of experimental skin infections induced by drug-resistant herpes simplex virus mutants.
    Klein RJ; Friedman-Kien AE; DeStefano E
    Infect Immun; 1981 Dec; 34(3):693-701. PubMed ID: 6277789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir.
    McLaren C; Chen MS; Ghazzouli I; Saral R; Burns WH
    Antimicrob Agents Chemother; 1985 Dec; 28(6):740-4. PubMed ID: 3002245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An acyclovir-resistant strain of herpes simplex virus type 2 which is highly virulent for mice.
    Sakuma S; Yamamoto M; Kumano Y; Mori R
    Arch Virol; 1988; 101(3-4):169-82. PubMed ID: 2845890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus.
    Field HJ; Darby G; Wildy P
    J Gen Virol; 1980 Jul; 49(1):115-24. PubMed ID: 6252285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance.
    Darby G; Field HJ; Salisbury SA
    Nature; 1981 Jan; 289(5793):81-3. PubMed ID: 6256650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs.
    Field H; McMillan A; Darby G
    J Infect Dis; 1981 Feb; 143(2):281-5. PubMed ID: 6260876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient.
    Schnipper LE; Crumpacker CS; Marlowe SI; Kowalsky P; Hershey BJ; Levin MJ
    Am J Med; 1982 Jul; 73(1A):387-92. PubMed ID: 6285729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of bromovinyldeoxyuridine-resistant strains of herpes simplex virus and successful chemotherapy of mice infected with one such strain by using acyclovir.
    Field HJ; Neden J
    Antiviral Res; 1982 Oct; 2(5):243-54. PubMed ID: 6295272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility to acyclovir of herpes simplex virus isolates obtained between 1977 and 1996 in Japan.
    Hasegawa T; Kawana T; Okuda T; Horii M; Tsukada T; Shiraki K
    J Med Virol; 2001 Jan; 63(1):57-63. PubMed ID: 11130888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection.
    Klein RJ; DeStefano E; Brady E; Friedman-Kien AE
    Arch Virol; 1980; 65(3-4):237-46. PubMed ID: 6251784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease and latency characteristics of clinical herpes virus isolated after acyclovir therapy.
    Sibrack CD; McLaren C; Barry DW
    Am J Med; 1982 Jul; 73(1A):372-5. PubMed ID: 6285725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
    Spector T; Lobe DC; Ellis MN; Blumenkopf TA; Szczech GM
    Antimicrob Agents Chemother; 1992 May; 36(5):934-7. PubMed ID: 1324641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey.
    Nugier F; Colin JN; Aymard M; Langlois M
    J Med Virol; 1992 Jan; 36(1):1-12. PubMed ID: 1315366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine).
    Smith KO; Kennell WL; Poirier RH; Lynd FT
    Antimicrob Agents Chemother; 1980 Feb; 17(2):144-50. PubMed ID: 6247967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis of acyclovir-resistant herpes simplex type 2 isolates in animal models of genital herpes: models for antiviral evaluations.
    Bernstein DI; Ireland J; Bourne N
    Antiviral Res; 2000 Sep; 47(3):159-69. PubMed ID: 10974368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes simplex acyclovir-resistant mutant in experimental keratouveitis.
    Boisjoly HM; Park NH; Pavan-Langston D; De Clercq E
    Arch Ophthalmol; 1983 Nov; 101(11):1782-6. PubMed ID: 6314952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues.
    Bestman-Smith J; Schmit I; Papadopoulou B; Boivin G
    J Virol; 2001 Apr; 75(7):3105-10. PubMed ID: 11238837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.